ArticleScientific reports2026
Photodynamic therapy induces pyroptosis via GSDMD pathway in NCI-H226 human lung squamous carcinoma cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Photodynamic therapy (PDT) is a promising minimally invasive anticancer strategy with high tumor-targeting specificity, attracting considerable attention in oncology. Pyroptosis, a pro-inflammatory programmed cell death (PCD) mediated by the gasdermin (GSDM) family, is tightly regulated by the gasdermin D (GSDMD)-dependent pathway and contributes to tumor regulation. However, the molecular mechanism of PDT-induced pyroptosis in lung squamous cell carcinoma (LUSC) NCI-H226 cells remains unclear. Herein, we demonstrated that PDT effectively triggers GSDMD-mediated pyroptosis in NCI-H226 cells, with typical morphological features including cytoplasmic bubble formation, membrane rupture, intracellular content release and pro-inflammatory mediator secretion. Mechanistically, PDT-induced pyroptosis involves NLRP3 inflammasome upregulation, caspase-1 activation and GSDMD cleavage to generate GSDMD-N, key events driving pyroptosis. PDT treatment significantly enhanced lactate dehydrogenase (LDH) release and secretion of pro-inflammatory cytokines including IL-1β and IL-18. Notably, GSDMD silencing or caspase-1 inhibition with VX765 markedly abrogated PDT-induced pyroptosis. Collectively, PDT induces pyroptosis in NCI-H226 cells via the NLRP3-caspase-1-GSDMD axis. This study reveals a novel anti-tumor mechanism of PDT in LUSC, providing a theoretical basis and potential therapeutic targets for clinical LUSC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.